Health The FDA approved Eli Lilly’s orforglipron (Foundayo), the first daily oral GLP-1 obesity pill with no food or water restrictions, on 1 April 2026. Widespread access, as always, is approximately two weeks away. 2 By goober Jul 19, 2026 31 views
